Dyne Therapeutics (NASDAQ:DYN) Posts Quarterly Earnings Results, Misses Estimates By $0.33 EPS

Dyne Therapeutics (NASDAQ:DYN) announced its earnings results on Thursday. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33), FiscalAI reports.

Dyne Therapeutics Stock Down 2.1%

Shares of DYN opened at $25.18 on Friday. The stock has a 50 day moving average price of $21.24 and a 200 day moving average price of $18.87. Dyne Therapeutics has a one year low of $9.57 and a one year high of $26.26. The company has a debt-to-equity ratio of 0.28, a quick ratio of 19.92 and a current ratio of 12.02. The stock has a market capitalization of $4.70 billion, a price-to-earnings ratio of -7.56 and a beta of 1.06.

Insiders Place Their Bets

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 480,240 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $22.79, for a total value of $10,944,669.60. Following the transaction, the director owned 875,912 shares in the company, valued at approximately $19,962,034.48. This trade represents a 35.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders acquired 9,000 shares of company stock valued at $156,800 and sold 1,665,542 shares valued at $36,321,576. Insiders own 9.46% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds have recently modified their holdings of DYN. Creative Planning lifted its stake in shares of Dyne Therapeutics by 6.8% in the third quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after buying an additional 986 shares in the last quarter. Caxton Associates LLP grew its stake in Dyne Therapeutics by 10.9% during the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after acquiring an additional 1,627 shares in the last quarter. Steward Partners Investment Advisory LLC grew its stake in Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Dyne Therapeutics by 5.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after acquiring an additional 2,886 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its holdings in Dyne Therapeutics by 12.1% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 33,547 shares of the company’s stock valued at $656,000 after acquiring an additional 3,628 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on DYN shares. Sanford C. Bernstein boosted their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Wall Street Zen lowered shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a research note on Friday, May 15th. Finally, Morgan Stanley reduced their price target on shares of Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating for the company in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $34.42.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.